中金：首予瑞博生物-B(06938)“跑赢行业”评级目标价100港元

智通财经网02-20

智通财经APP获悉，中金发布研报称，首次覆盖瑞博生物-B(06938)给予跑赢行业评级，基于DCF，该行给予目标价100.0港元，较公司当前股价存在44.9%的上行空间。中金主要观点如下：瑞博是小核酸药物开发的全球领军者，拥有经验证的成熟小核酸药物开发平台2007年成立至今，公司已拥有自主研发的GalNAc肝靶向RiboGalSTAR平台，并从肝靶向逐步走向肝外靶向;公司也持续迭代化学修饰，增强...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2612230236?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","is_english":false,"pubTime":"2026-02-20 09:58","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2612230236","market":"hk","top_or_hot":-1,"title":"中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，中金发布研报称，首次覆盖瑞博生物-B(06938)给予跑赢行业评级，基于DCF，该行给予目标价100.0港元，较公司当前股价存在44.9%的上行空间。中金主要观点如下：瑞博是小核酸药物开发的全球领军者，拥有经验证的成熟小核酸药物开发平台2007年成立至今，公司已拥有自主研发的GalNAc肝靶向RiboGalSTAR平台，并从肝靶向逐步走向肝外靶向;公司也持续迭代化学修饰，增强...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1405976.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-20 09:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1405976.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中金发布研报称，首次覆盖瑞博生物-B(06938)给予跑赢行业评级，基于DCF，该行给予目标价100.0港元，较公司当前股价存在44.9%的上行空间。中金主要观点如下：瑞博是小核酸药物开发的全球领军者，拥有经验证的成熟小核酸药物开发平台2007年成立至今，公司已拥有自主研发的GalNAc肝靶向RiboGalSTAR平台，并从肝靶向逐步走向肝外靶向;公司也持续迭代化学修饰，增强...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1405976.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1405976.html","article_id":"2612230236","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20260220/20260220094929_32902.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612230236","pubTimestamp":1771552683,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"06938":"瑞博生物-B"},"translate_title":"CICC: For the first time, Ruibo Biotech-B (06938) was given an \"outperform industry\" rating with a target price of HK $100","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1.5},"content_text":"智通财经APP获悉，中金发布研报称，首次覆盖瑞博生物-B(06938)给予跑赢行业评级，基于DCF，该行给予目标价100.0港元，较公司当前股价存在44.9%的上行空间。中金主要观点如下：瑞博是小核酸药物开发的全球领军者，拥有经验证的成熟小核酸药物开发平台2007年成立至今，公司已拥有自主研发的GalNAc肝靶向RiboGalSTAR平台，并从肝靶向逐步走向肝外靶向;公司也持续迭代化学修饰，增强靶点特异性和序列兼容性，并减少脱靶效应，赋能疗效和安全性升级。截至25年底，公司在全球主要司法管辖区域共有473件专利及专利申请，借此构建了全面的知识产权组合。更重要的是，除分子设计之外，公司研发平台具备全技术链条整合能力，实现从CMC生产、早期研究到商业化的全生命周期覆盖，是公司管线推进的效率保障。瑞博是目前拥有最多临床资产的中国小核酸企业之一截至25年底，公司已拥有7款进入临床阶段的siRNA管线，其中4款处于II期，RBD4059(FXI)、RBD5044(ApoC3)、RBD1016(HBV)是核心资产。RBD4059是全球首个且临床进展最快的用于治疗血栓性疾病的FXI  siRNA药物，将于2026年启动IIb期临床，涉及多个血栓疾病;RBD5044是全球第二个进入临床阶段的ApoC3  siRNA，进度仅次于Arrowhead;RBD1016正在验证在HBV的成药性。该行与市场的最大不同?市场担心FXI抑制剂的成药性，该行认为FXI抑制剂至少在脑卒中、膝关节置换术后等适应症已验证成药性，FXI  siRNA有望凭借更高的靶点抑制率攻克房颤适应症。潜在催化剂行业FXI抑制剂和ApoC3 siRNA数据映射，瑞博多个小核酸药物II期临床启动和数据读出。风险临床试验数据不及预期，竞争格局恶化风险，行业内同靶点研发失败风险，现金流压力。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612230236","isCrawlerRequest":true}

中金：首予瑞博生物-B(06938)“跑赢行业”评级 目标价100港元

精彩评论

中金：首予瑞博生物-B(06938)“跑赢行业”评级目标价100港元